VVX001 / Viravaxx - LARVOL DELTA

VVX001 Induces preS-Specific Antibodies Reacting to Common HBV Genotypes in Hepatitis B Virus (HBV) Carrier Mice. (PubMed, Vaccines (Basel)) - "Actively immunized AAV-HBV-treated mice had a higher number of intrahepatic lymphocytes than vehicle-vaccinated and mock-transduced animals. These findings encourage performing further trials to study the potential of VVX001 for therapeutic vaccination against CHB."

Journal • Preclinical • Allergy • Hepatitis B • Immunology • Infectious Disease • Inflammation

The PreS-Based Recombinant Vaccine VVX001 Induces Hepatitis B Virus Neutralizing Antibodies in a Low-Responder to HBsAg-Based HBV Vaccines. (PubMed, Vaccines (Basel)) - "BM32 is a recombinant grass pollen allergy vaccine containing the HBV-derived preS surface antigen as an immunological carrier protein. Maximal HBV neutralization (98.4%) in vitro was achieved 1 month after the last injection, which correlated with the maximal IgG reactivity to the N-terminal part of preS. Our data suggest that VVX001 may be used as a preventive vaccination against HBV even in non-responders to HBsAg-based HBV vaccines."

Journal • Allergy • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • CD4

Induction of pre-s antobodies in HBeAg negative chronic hepatitis B patients by thereupatic vaccination with the pre-s based vaccine VVX001 - interim analysis (EASL-ILC 2022) - P2 | "Five patients received placebo and 15 received VXX001. VVX001 is safe and well tolerated and induces a preSspecific immune response in patients with chronic HBeAg-neg hepatitis B. In 87% of vaccinated patients, no repeated treatment with NUCs was necessary after stopping NUCs. A longer follow-up is needed to evaluate the long-term impact of vaccination and stop of NUC therapy."

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD4 • CD8

[VIRTUAL] VVX001 INDUCES ROBUST PRE-S-SPECIFIC IMMUNITY IN PATIENTS CHRONICALLY INFECTED WITH HEPATITIS B (AASLD 2021) - P2 | "VVX001 is safe and well tolerated and induces a preS-specific immune response in vaccine naïve subjects and in patients chronically infected with HBV, but classified as inactive carriers. Whether this immune response can be used to achieve functional cure in patients with active chronic HBV infection remains to be determined in further studies ."

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD4 • CD8

Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001 (clinicaltrials.gov) - P2; N=84; Recruiting; Sponsor: Viravaxx AG; Phase classification: P1/2 ➔ P2

Phase classification • Hepatitis B • Hepatology • Infectious Disease • CD4